9 results about "Contrast-induced nephropathy" patented technology

A quantitative, ultrashort time to echo, contrast-enhanced magnetic resonance imaging technique is provided. The technique can be used to accurately measure contrast agent concentration in the blood, to provide clear, high-definition angiograms, and to measure absolute quantities of cerebral blood volume on a voxel-by-voxel basis.

This invention discloses a method and system for adjusting and optimizing CT contrast-enhanced scanning parameters, comprising: acquiring the patient's physiological characteristic parameters and injection parameters, and calculating the contrast agent concentration at the target site at different times based on the physiological characteristic parameters and injection parameters, generating a time-density curve. The enhancement coefficient corresponding to the current peak voltage of the X-ray tube is determined using the CT contrast-enhanced curve, and the time-enhanced value curve of the current target site is determined by combining the time-density curve. The peak enhancement value is determined based on the scanning time window and the time-enhanced value curve, and the peak enhancement value is compared with the enhancement target. If the peak enhancement value does not meet the enhancement target, the injection parameters or scanning parameters are adjusted, and the peak enhancement value is recalculated and compared with the enhancement target. This process continues until the peak enhancement value meets the enhancement target. This method can automatically search and decide on the optimal CT contrast-enhanced scanning scheme in reverse, solving the problem of unsatisfactory CT scan results.

The application discloses a contrast agent for enhancing the effect of ELCA volume reduction, and belongs to the field of medical reagents, and particularly relates to a contrast agent which comprises a heparin-based compound and a contrast agent, wherein the heparin-based compound comprises heparin, and the content of the heparin-based compound in the contrast agent is 2-64 mu g / mL. The contrast agent comprises at least one of iopromide and iodixanol. The heparin-based compound further comprises a heparin derivative, and the heparin derivative is prepared by subjecting heparin to oxidation and then to reaction with a derivatizing agent. The derivatizing agent comprises L-alanyl-L-proline methyl ester hydrochloride. The application is a contrast agent which can be combined with ELCA, enhances the effect of ELCA volume reduction, has a good effect on blood vessel plaque erosion, and has high shock wave pressure when combined with excimer laser.

The application discloses a novel bismuth-based chelate CT contrast agent and a preparation method and application thereof. The synthesis method comprises the following steps: 2,6-pyridine dimethyl alcohol is reacted with chlorosulfoxide to obtain 2,6-bis(chloromethyl)pyridine; the 2,6-bis(chloromethyl)pyridine is reacted with N,N',N''-tris(p-tolylsulfonyl)divinyltriamine and an inorganic base in a solvent and is heated, is deprotected by concentrated sulfuric acid to obtain an intermediate pyclen; the pyclen is heated and reacted with a halogenated carboxylic acid ester under alkaline conditions in a polar organic solvent, is hydrolyzed to obtain a ligand product; and the ligand product is heated and chelated with a bismuth agent to obtain the target bismuth-based chelate. The application realizes the laboratory scale preparation of the small-molecule bismuth-based chelate CT contrast agent, and a non-ionic contrast agent is prepared, which has low osmotic pressure, high stability, high water solubility and good biological safety and is used for CT imaging of the digestive system, the urinary system and the circulatory system.

This invention discloses a method and device for monitoring contrast agent extravasation, belonging to the field of medical device technology. The method involves dividing the contrast agent injection area into a proximal and distal needle region by identifying the center coordinates of the injection area; projecting a plurality of laser lines onto the proximal and distal needle regions based on the center coordinates; monitoring the deformation difference of the laser lines in the proximal needle region and the intensity ratio of the laser lines in the proximal and distal needle regions based on the laser lines during injection; determining the presence of contrast agent extravasation risk and issuing an alarm command when the deformation difference is not less than a preset deformation threshold and the intensity ratio is not greater than a preset intensity threshold. Therefore, this invention effectively solves the problems of high misdiagnosis rate and low real-time performance in existing technologies.

Systems and methods for medical contrast imaging are disclosed. Systems and methods of the present disclosure address the challenges of continental medical Imaging by, for example, using contrast agents that facilitate use of low-risk wavelengths of imaging radiation, and / or by using imaging methods that facilitate imaging with resolution and / or image quality that are adequate for diagnosis, treatment, and / or any other suitable purposefs). Examples of suitable wavelengths for the imaging radiation may include certain microwave and / or radio- frequency wavelengths that pose little to no health hazards.

The application discloses a photon CT low-dose low-concentration contrast agent scheme coronary stenosis evaluation system and belongs to the medical image field.The photon CT low-dose low-concentration contrast agent scheme coronary stenosis evaluation system comprises a multi-energy spectrum data acquisition unit, a data preprocessing unit, an image generation unit, an image segmentation unit, a plaque analysis unit and a stenosis detection unit.The application solves the problems of high radiation dose, large amount of contrast agent and low efficiency and strong subjectivity caused by high dependence on the experience of doctors in the existing coronary CT examination, realizes high-quality coronary imaging and accurate stenosis evaluation under the condition of low dose and low-concentration contrast agent by adopting a photon counting CT detector and optimized low-dose scanning parameters, combining a deep learning algorithm and a multi-material decomposition technology, significantly reduces the radiation exposure and contrast agent related risk of patients, and improves the accuracy and reliability of coronary stenosis detection and plaque component analysis.

This application discloses a syringe assembly control method and related device to improve testing accuracy. This application embodiment is applied to a control module in a computed tomography (CT) system. The system further includes a syringe assembly. The method includes: obtaining the iodine injection flow rate of a specified iodine contrast agent; obtaining a target injection coefficient, the target injection coefficient being in the range of 1.5 to 2; calculating, based on a preset algorithm, a saline injection flow rate of physiological saline, which is proportional to the iodine injection flow rate, according to the iodine injection flow rate and the target injection coefficient; and sending an injection command including the saline injection flow rate and the iodine injection flow rate to the syringe assembly, so that the syringe assembly first injects physiological saline into the patient at the saline injection flow rate, and then injects the specified iodine contrast agent at the iodine injection flow rate.

This disclosure relates to fibroin-specific and collagen-specific imaging agents comprising metal oxide nanoparticles.